Show simple item record

dc.contributor.authorSaumell Esnaola, Miquel
dc.contributor.authorElejaga Jimeno, Ainhoa
dc.contributor.authorEcheazarra Escudero, Leire
dc.contributor.authorBorrega Román, Leire
dc.contributor.authorBarrondo Lacarra, Sergio ORCID
dc.contributor.authorLópez de Jesús, Maider ORCID
dc.contributor.authorGonzález Burguera, Imanol
dc.contributor.authorGomez-Caballero, Alberto
dc.contributor.authorGoicolea Altuna, María Aranzazu ORCID
dc.contributor.authorSallés Alvira, Joan
dc.contributor.authorGarcía del Caño, Gontzal
dc.date.accessioned2022-11-02T17:33:43Z
dc.date.available2022-11-02T17:33:43Z
dc.date.issued2022
dc.identifier.citationMicrobial Cell Factories 21 : (2022) // Article ID 192es_ES
dc.identifier.issn1475-2859
dc.identifier.urihttp://hdl.handle.net/10810/58236
dc.description.abstractBackground: Replacement of radioligand binding assays with antibody-antigen interaction-based approaches for quantitative analysis of G protein-coupled receptor (GPCR) levels requires the use of purified protein standards containing the antigen. GPCRs in general and cannabinoid CB1 receptor in particular show a progressive tendency to aggregate and precipitate in aqueous solution outside of their biological context due to the low solubility that the hydrophobic nature imprinted by their seven transmembrane domains. This renders full-length recombinant GPCRs useless for analytical purposes, a problem that can be overcome by engineering soluble recombinant fragments of the receptor containing the antigen. Results: Here we generated highly soluble and stable recombinant protein constructs GST-CB1(41)(4-)(472 )and GST-CB1(414-442) containing much of the human CB1 receptor C-terminal tail for use as standard and negative control, respectively, in quantitative Western blot analysis of CB1 receptor expression on crude synaptosomes of the adult rat brain cortex. To this end we used three different antibodies, all raised against a peptide comprising the C-terminal residues 443-473 of the mouse CB1 receptor that corresponds to residues 442-472 in the human homolog. Estimated values of CB1 receptor density obtained by quantitative Western blot were of the same order of magnitude but slightly higher than values obtained by the radioligand saturation binding assay. Conclusions: Collectively, here we provide a suitable Western blot-based design as a simple, cost-effective and radioactivity-free alternative for the quantitative analysis of CB1 receptor expression, and potentially of any GPCR, in a variety of biological samples. The discrepancies between the results obtained by quantitative Western blot and radioligand saturation binding techniques are discussed in the context of their particular theoretical bases and methodological constraints.es_ES
dc.description.sponsorshipThis work was funded by Spanish Ministry of Science, Innovation and Universities (Grant ID, CTQ2017-85686-R) and Basque Government (Research Groups of the Basque University System, Grant IDs, IT1492-22 and IT1620-22).es_ES
dc.language.isoenges_ES
dc.publisherBMCes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectGPCR expression analysises_ES
dc.subjectquantitative western blotes_ES
dc.subjectradioligand saturation bindinges_ES
dc.subjectcannabinoid CB1 receptor antibodieses_ES
dc.subjectcarboxy-terminal tailes_ES
dc.subjectsoluble recombinant protein standardses_ES
dc.subjectGST fusion proteinses_ES
dc.titleDesign and validation of recombinant protein standards for quantitative Western blot analysis of cannabinoid CB1 receptor density in cell membranes: an alternative to radioligand binding methodses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://microbialcellfactories.biomedcentral.com/articles/10.1186/s12934-022-01914-1es_ES
dc.identifier.doi10.1186/s12934-022-01914-1
dc.departamentoesFarmacologíaes_ES
dc.departamentoesFisiologíaes_ES
dc.departamentoesNeurocienciases_ES
dc.departamentoesQuímica analíticaes_ES
dc.departamentoeuFarmakologiaes_ES
dc.departamentoeuFisiologiaes_ES
dc.departamentoeuKimika analitikoaes_ES
dc.departamentoeuNeurozientziakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Except where otherwise noted, this item's license is described as © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.